It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
At present, it is commonly believed that tRFs and tiRNAs are formed by the specific and selective shear of tRNAs under certain pressure stimulation, rather than by random degradation of tRNA. tRFs and tiRNAs have been reported to contribute to the biological process of a variety of human cancers. However, the evidence for the mechanisms of tRFs and tiRNAs in the occurrence and development of gastric cancer (GC) is still insufficient. Here, we aimed to explore the carcinogenic roles of tRFs and tiRNAs in GC with RNA-sequencing technique, and found a novel 3’tRNA-derived fragment tRF-Val was significantly upregulated in GC tissues and cell lines. tRF-Val expression was positively correlated with tumor size and the depth of tumor invasion in GC tissues. Functionally, tRF-Val promoted proliferation and invasion, and inhibited apoptosis in GC cells. Mechanistically, tRF-Val directly bound to the chaperone molecule EEF1A1, mediated its transport into the nucleus and promoted its interaction with MDM2 (a specific p53 E3 ubiquitin ligase), thus inhibiting the downstream molecular pathway of p53 and promoting GC progression. These findings provided a new potential therapeutic target for GC and a new explanation for the occurrence of GC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Shandong University, Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Jinan, China (GRID:grid.27255.37) (ISNI:0000 0004 1761 1174); Shandong Provincial Hospital Affiliated to Shandong First Medical University, Department of Gastrointestinal Surgery, Jinan, China (GRID:grid.460018.b) (ISNI:0000 0004 1769 9639); Shandong Provincial Hospital, Shandong Provincial Laboratory of Translational Medicine Engineering for Digestive Tumors, Jinan, China (GRID:grid.460018.b) (ISNI:0000 0004 1769 9639)
2 the First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Department of Gastrointestinal Surgery, Jinan, China (GRID:grid.452422.7) (ISNI:0000 0004 0604 7301)
3 Shandong University, Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Jinan, China (GRID:grid.27255.37) (ISNI:0000 0004 1761 1174)
4 Shandong Provincial Hospital Affiliated to Shandong First Medical University, Department of Gastrointestinal Surgery, Jinan, China (GRID:grid.460018.b) (ISNI:0000 0004 1769 9639)